Literature DB >> 25266882

Potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis.

Zhang Feng1, Zhan Yinchu, Shi Yinsheng, Wu Fengqing, Zhou Xiaoyang, Li Jin, Gao Xiaofei.   

Abstract

Severe acute pancreatitis is a life threatening disease with a high rate of mortality, but its treatments are still controversial. The purpose of this study is to investigate the potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Intraperitoneal injection of 50 μg/kg caerulein for seven times (every interval time was an hour) and intraperitoneal injection of 10 mg/kg lipopolysaccharide for once to establish acute pancreatitis mice models. One hundred sixty specific pathogen-free imprinting control region (ICR) female mice were randomly divided into the control group (group A, normal saline), the mild group (group B, caerulein), the severe group (group C, caerulein + lipopolysaccharide), and the intervention group (group D, S100A12 recombinant antibodies + caerulein + lipopolysaccharide); each group had 40 mice. We sampled the blood at 8, 12, and 24 h after the beginning of building animal models. In each period of time, we respectively detected the serum S100A12, amylase (AMY), C-reactive protein (CRP), interleukin (IL-1β, IL-6), and tumor necrosis factor (TNF-α) levels. In addition, we observed and scored the pancreas and lungs histopathology of the mice. In each same period of time compared with group C, serum AMY, CRP, IL-1β, IL-6, TNF-α levels of group D were significantly decreased (p < 0.05). In each same period of time compared with group B and group C, serum S100A12 concentration of group D was significantly decreased (p < 0.05), and the pancreas and lungs histopathology were also much improved. These observations demonstrate that S100A12 recombinant antibodies were able to significantly reduce the severity of acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Serum S100A12 may serve as a useful marker for disease severity and curative effect in mice with severe acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25266882     DOI: 10.1007/s10753-014-0032-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  34 in total

1.  Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis.

Authors:  Hua Liao; Jiang Wu; Eric Kuhn; Wendy Chin; Betty Chang; Michael D Jones; Steve O'Neil; Karl R Clauser; Johann Karl; Fritz Hasler; Ronenn Roubenoff; Werner Zolg; Brad C Guild
Journal:  Arthritis Rheum       Date:  2004-12

2.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.

Authors:  Christophe Rosty; Laurence Christa; Scott Kuzdzal; William M Baldwin; Marianna L Zahurak; Françoise Carnot; Daniel W Chan; Marcia Canto; Keith D Lillemoe; John L Cameron; Charles J Yeo; Ralph H Hruban; Michael Goggins
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

3.  Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease.

Authors:  C E Shepherd; J Goyette; V Utter; F Rahimi; Z Yang; C L Geczy; G M Halliday
Journal:  Neurobiol Aging       Date:  2005-10-25       Impact factor: 4.673

4.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 5.  Current management of acute pancreatitis.

Authors:  Julia Mayerle; Verena Hlouschek; Markus M Lerch
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-10

6.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

7.  Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases.

Authors:  Eva Lorenz; Marianne S Muhlebach; Philippe A Tessier; Neil E Alexis; R Duncan Hite; Michael C Seeds; David B Peden; Wayne Meredith
Journal:  Respir Med       Date:  2007-12-27       Impact factor: 3.415

Review 8.  Human S100A12: a novel key player in inflammation?

Authors:  Jens Pietzsch; Susan Hoppmann
Journal:  Amino Acids       Date:  2008-04-29       Impact factor: 3.520

9.  S100A12 (EN-RAGE) in monitoring Kawasaki disease.

Authors:  Dirk Foell; Fukiko Ichida; Thomas Vogl; Xianyi Yu; Rui Chen; Toshio Miyawaki; Clemens Sorg; Johannes Roth
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

10.  Identification and characterization of a novel human neutrophil protein related to the S100 family.

Authors:  F Guignard; J Mauel; M Markert
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

View more
  3 in total

1.  TRAM1 protects AR42J cells from caerulein-induced acute pancreatitis through ER stress-apoptosis pathway.

Authors:  Yongxia Cai; Yanbo Shen; Guangling Xu; Ran Tao; Weiyan Yuan; Zhongwei Huang; Dongmei Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-04-22       Impact factor: 2.416

2.  Comment on "Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis".

Authors:  Vahid Bagheri; Carolyn L Geczy
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

3.  Human Plasma Transcriptome Implicates Dysregulated S100A12 Expression: A Strong, Early-Stage Prognostic Factor in ST-Segment Elevated Myocardial Infarction: Bioinformatics Analysis and Experimental Verification.

Authors:  Hu Zhai; Lei Huang; Yijie Gong; Yingwu Liu; Yu Wang; Bojiang Liu; Xiandong Li; Chunyan Peng; Tong Li
Journal:  Front Cardiovasc Med       Date:  2022-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.